
ADC Therapeutics (ADCT) Stock Forecast & Price Target
ADC Therapeutics (ADCT) Analyst Ratings
Bulls say
ADC Therapeutics's stock outlook is supported by the advancement of its discounted cash flow (DCF)-based valuation, which reflects a raised price target due to positive developments in its clinical studies, specifically the potential for label expansion for ZYNLONTA. The company's strategy to secure funding through a $60 million PIPE financing with institutional investors strengthens its financial position, enabling further investment in its promising development pipeline, including multiple ongoing trials. Moreover, the anticipated outcomes from the multicenter study may enhance the product's market presence, particularly in the second-line treatment setting in combination with existing therapies like rituximab.
Bears say
ADC Therapeutics has outlined significant financial challenges, including a recorded net loss of $0.04 per share in 4Q25, which, while narrower than prior estimates, still indicates ongoing financial struggles. The company faces substantial risks related to the approval and market uptake of its lead product, ADCT-402, as well as potential failures within its pipeline, contributing to a negative outlook. Additionally, the risk of medium- to long-term dilution further exacerbates concerns regarding the firm's financial stability and growth prospects.
This aggregate rating is based on analysts' research of ADC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ADC Therapeutics (ADCT) Analyst Forecast & Price Prediction
Start investing in ADC Therapeutics (ADCT)
Order type
Buy in
Order amount
Est. shares
0 shares